CAFCW117 A Scalable, Validated Platform for Generative Lead Optimization of De Novo Molecules: Case Study in Discovery of Potent, Selective Aurora Kinase Inhibitors with Favorable Secondary Pharmacology
By Andrew Weber
Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium GlaxoSmithKline